Influenza Management Resources

Diagnosing, Managing and Tracking Influenza

Use the following resources to support your knowledge of influenza as part of your patient care.

Some of these resources require Adobe® Reader®. Get the free Adobe® Reader®.

Diagnosis and Management

  • Simplify prescription writing during influenza season by printing Tamiflu dosing instructions for influenza treatment, post-exposure prophylaxis, and seasonal prophylaxis in adults and children aged 1 year and older.

  • Refresh your understanding of the benefits of Tamiflu for adults - how it can shorten the duration of the flu and help protect other family members in the house.

  • Learn how you can help shorten the duration of the flu in children, and reduce the chances of spreading the flu to family members when Tamiflu is prescribed.

  • Help your patients learn about the flu, the difference between the flu and the common cold, and tips for preventing and treating the flu.

  • A comparison of Cold vs Flu Symptoms. Help your patients understand the difference, as well as provide them with tips for prevention and treatment of the flu.

  • CDC Seasonal Influenza Site

    A comprehensive collection of influenza resources for patients and healthcare professionals including patient materials and seasonal influenza guidelines.

Track the Spread of Influenza

  • FluSTAR® System for Tracking and Reporting Flu

    Access to timely information about current levels of influenza circulating in the community is a key factor in accurate early diagnosis and management of influenza. A unique, comprehensive surveillance system, the FluSTAR System for Tracking and Reporting Flu is now available to bring this information directly to healthcare professionals, patients and public health officials. FluSTAR provides crucial, up-to-date information about the changing local and national status of influenza across the country via a Web site and e-mail alerts. This module has been designed to familiarize you and your audience with the components, operation and benefits of the FluSTAR system

    Visit FluSTAR.com

Learn about TAMIFLU for influenza treatment and influenza prevention.

Influenza Resources

Download information about treatment and
prevention of influenza:

Browse other resources for Diagnosing,
Managing and Tracking Influenza.

Be Prepared for Flu Season

Help manage the impact of influenza season on your practice.

Review Office Preparation Tips

Get the free Adobe® Reader®

Important Safety Information

Indications

TAMIFLU is indicated for the treatment of uncomplicated influenza caused by viruses types A and B in patients 1 year and older who have been symptomatic for no more than 2 days.

TAMIFLU is also indicated for the prophylaxis of influenza in patients 1 year and older.

TAMIFLU is not a substitute for early and annual vaccination as recommended by the Centers for Disease Control's Advisory Committee on Immunization Practices (ACIP).

Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use TAMIFLU.

Safety Information

There is no evidence for efficacy against any illness caused by agents other than influenza types A and B.

Treatment efficacy in subjects with chronic cardiac and/or respiratory disease has not been established. No difference in the incidence of complications was observed between the treatment and placebo groups in this population.

No information is available regarding treatment of influenza in patients at imminent risk of requiring hospitalization.

Efficacy of TAMIFLU has not been established in immunocompromised patients.

Safety and efficacy of repeated treatment or prophylaxis courses have not been studied.

Influenza can be associated with a variety of neurologic and behavioral symptoms, which can include events such as hallucinations, delirium and abnormal behavior, in some cases resulting in fatal outcomes. These events may occur in the setting of encephalitis or encephalopathy but can occur without obvious severe disease. There have been postmarketing reports (mostly from Japan) of delirium and abnormal behavior leading to injury, and in some cases resulting in fatal outcomes, in patients with influenza who were receiving TAMIFLU. Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made but they appear to be uncommon based on TAMIFLU usage data. These events were reported primarily among pediatric patients and often had an abrupt onset and rapid resolution. The contribution of TAMIFLU to these events has not been established. Patients with influenza should be closely monitored for signs of abnormal behavior. If neuropsychiatric symptoms occur, the risks and benefits of continuing treatment should be evaluated for each patient.

In postmarketing experience, rare cases of anaphylaxis and serious skin reactions, including toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme, have been reported with TAMIFLU.

The most common adverse events reported >1% of patients treated with TAMIFLU and more commonly than in patients treated with placebo are:

  • Treatment of adult and pediatric patients - nausea, vomiting.
  • Prophylaxis of adult and pediatric patients - nausea, vomiting, abdominal pain.

Vaccination is considered the first line of defense against influenza.

THIS SITE IS INTENDED FOR U.S. AUDIENCES ONLY.

Copyright © 2006-2009 Roche Laboratories Inc. All rights reserved. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Statement.